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Background: Urinary bladder carcinoma stage T1 is an unpredictable disease that in some cases has a good
prognosis with only local or no recurrence, but in others can appear as a more aggressive tumor with progression
to more advanced stages. The aim here was to investigate stage T1 tumors regarding MDM2 promoter SNP309
polymorphism, mutations in the p53 gene, and expression of p53 and p16 measured by immunohistochemistry,
and subsequently relate these changes to tumor recurrence and progression. We examined a cohort of patients
with primary stage T1 urothelial carcinoma of the bladder and their tumors.
Methods: After re-evaluation of the original slides and exclusions, the study population comprised 141 patients, all
with primary stage T1 urothelial carcinoma of the bladder. The hospital records were screened for clinical
parameters and information concerning presence of histologically proven recurrence and progression. The
paraffin-embedded tumor material was evaluated by immunohistochemistry. Any mutations found in the p53 gene
were studied by single-strand conformation analysis and Sanger sequencing. The MDM2 SNP309 polymorphism was
investigated by pyrosequencing. Multivariate analyses concerning association with prognosis were performed, and
Kaplan-Meier analysis was conducted for a combination of changes and time to progression.
Results: Of the 141 patients, 82 had at least one MDM2 SNP309 G allele, and 53 had a mutation in the p53 gene,
but neither of those anomalies was associated with a worse prognosis. A mutation in the p53 gene was associated
with immunohistochemically visualized p53 protein expression at a cut-off value of 50%. In the group with p53
mutation Kaplan-Meier analysis showed higher rate of progression and shorter time to progression in patients with
immunohistochemically abnormal p16 expression compared to them with normal p16 expression (p = 0.038).
Conclusions: MDM2 SNP309 promoter polymorphism and mutations in p53 were not associated with worse
prognosis in this cohort of patients with primary stage T1 urinary bladder carcinoma. However, patients with
abnormal p16 expression and a mutated p53 gene had a higher rate of and a shorter time to progression, and p53
gene mutation was associated with an abnormal immunohistochemistry for p53 at a cut-off of 50%.Background
Urothelial carcinoma of the bladder (UCB) is an unpredict-
able disease, and this is particularly apparent in patients
with stage T1 UCB, who are at high risk of progression
(30–50%) [1,2]. The main treatment for non-muscle-
invasive bladder cancer (NMIBC) is transurethral resection
(TUR) combined with intravesical instillation of bacillus
Calmette-Guérin (BCG). Cystectomy is the treatment of* Correspondence: hansolsson33@telia.com
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reproduction in any medium, provided the orchoice in patients with a higher stage of UCB (≥ T2), in
spite of cystectomy, the prognosis is poor for these patients
[3]. Cystectomy can be considered for NMIBC stage T1,
however, performing cystectomy in every new case of stage
T1 UCB is overtreatment, and hence it is an essential as-
signment to identify markers that can assess prognosis and
aid individualization of treatment [4,5].
The molecular mechanism of tumor progression in UCB
is poorly understood. Several studies have tried to explain
the transformation from normal to malignant urothelium
and the progression that is often seen in this disease [6]. It
is known that UCB is strongly associated with alterations in
the p53 pathway [7]. Mutations in the p53 gene are often
correlated with higher tumor grade and more advancedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease [8].
The murine double minute 2 (MDM2) is a nega-
tive regulator of p53. Furthermore, MDM2 SNP 309
(rs2279744) promoter polymorphism has been reported to
be a risk modifier in several other malignant neoplasms
[9], but few studies have addressed the role of this as such
a modifier in UCB, which indicates the need for further
research on this subject [10].
MDM2 and p53 play a critical role in carcinogenesis
[11,12]. The latter is encoded by the p53 tumor suppres-
sor gene, and it induces cell cycle arrest, apoptosis, DNA
repair, and prevention of angiogenesis [13-15]. The p53
gene is often mutated in malignancies, which highlights
its importance in tumor development and progression.
MDM2, on the other hand, is an essential negative re-
gulator of p53, because, when present in excessive
amounts, it reduces the activity of p53 via enhanced
proteasomal degradation [12,16]. A single-nucleotide
polymorphism (SNP309, rs2279744) located in the first
intron of the core promoter region of the MDM2 gene
affects binding of the transcription factor Sp1. Sp1 binds
with higher affinity to the G allele than to the T allele,
which results in increased transcription of the MDM2
gene and higher levels of MDM2 protein, and thereby
inhibits the tumor suppressor function of p53 [17]. The
interaction between p53 and MDM2 is a target for the-
rapeutic intervention, and several such drugs are under
development or in clinical trials [18-20].
We have previously investigated clinical and histopatho-
logical parameters, as well as immunohistochemistry (IHC)
for proteins involved in cell cycle regulation ( i.e. p53, p21,
pRb, p16, and cyclin D1) and for matrix metalloproteina-
ses [21,22]. In those studies, we found that normal p53
(cut-off < 10%) was significantly associated with recurrence,
and abnormal p16 was associated with progression. It is
plausible that the mechanism for the latter relationship is
dependent on the step involving phosphorylation of Rb.
The importance of these proteins in tumor development
has been described by other researchers [23-25].
In the current study, we examined a population-based
cohort of patients with primary stage T1 UCB. We ana-
lyzed possible effects of the functional polymorphism
SNP309 in the MDM2 gene, and investigated the rela-
tionship between that polymorphism and mutations in
the p53 gene. We also evaluated the expression of p53,
p16, pRb and p21 measured by IHC. All findings were
evaluated regarding associations with the risk of progres-
sion and recurrence.
Patients and methods
The study population and histopathological re-evaluation
This population-based retrospective study included all
patients reported in 1992–2001 to the regional BladderCancer Registry of the Southeast Healthcare Region in
Sweden as having primary stage T1 UCB. The hospital
records were reviewed to collect information concerning
tumor characteristics (size and multiplicity), treatment
modalities, and outcome in relation to histologically pro-
ven recurrence and/or progression, as well as eventual
death from UCB. Definition of progression was recu-
rrence with infiltration to T2 or more, regional lymph
node involvement, distant metastasis, or death from
bladder cancer. Re-evaluation was done by one uropathol-
ogist (HO) on the original hematoxylin-eosin-stained
slides with respect to T stage [26], WHO grade [27], pres-
ence of concomitant carcinoma in situ, and lympho-
vascular infiltration (LVI) [28,29]. Presence of muscularis
propria was required for inclusion in the study. After the
re-evaluation, paraffin blocks were selected for sectioning
of new tumor material for further evaluations (see below).
The study cohort initially consisted of 285 patients,
and 141 remained after re-evaluation, reviewing of the
hospital records, and performance of the laboratory ana-
lyses. One important reason for exclusion was a changed
diagnosis in the re-evaluation (n = 52; 50 changed to Ta
and two to T2). Furthermore, seven patients had missing
specimens (both tissue blocks and slides), and 15 had
insufficient information in their hospital records (e.g.,
absence of tumor characteristics and/or details of fol-
low-up). In addition, due to a combination of poor tumor
quality and methodological difficulties in processing old
formalin-fixed tumor material for genetic analyses, tumor
material from 70 patients was excluded from further
laboratory analyses. In general, these 70 patients did not
differ substantially from the 141 that remained, although,
when we compared these two groups, we noted significant
differences with regard to age and p21 expression mea-
sured by IHC (Table 1).
When screening the hospital records, we found that
early re-resection, 4–6 weeks after initial TUR, was not
stipulated as mandatory during the period that the studied
material was collected, and hence this procedure had
been performed on only a very small number of patients
(included during the last years of the study period). The
presence of a tumor at a re-resection was considered to be
a recurrence. Random biopsies of normal mucosa were
not performed routinely, and no patient had received
intravesical BCG or chemotherapy before recurrence.
Immunohistochemical analysis
IHC was performed on 4-μm whole sections from the
original formalin-fixed, paraffin-embedded tissue blocks.
The blocks were carefully chosen, paying special atten-
tion to large tumor volume and good fixation. The sec-
tions were deparaffinized in xylene and then rehydrated,
pretreated with Tris-EDTA buffer (pH 9), and stained in
an automated immunostainer (DAKO TechMate-TM
Table 1 Comparison of the 60 patients that were
excluded from the study with the 141 that remained
(percentages calculated for the two groups)
60 excluded 141 remained Chi-square, significance
Age (years) 4.08, p = 0.04
≤ 73 38% 54%
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*LVI = lymphovascular invasion.
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monoclonal mouse antibodies (Table 2). Appropriate posi-
tive and negative controls were employed throughout. The
antibodies were initially individually optimized with respect
to the best pretreatment method and dilution. The ex-
pression levels were determined semi-quantitatively based
on the fraction of tumor cells showing positive staining
(0%, 1–10%, 11–25%, 26–50%, 51–75%, 76–100%). P53
was considered as abnormal when >10% positive tumor
cells, p16 was considered abnormal when no (0%) or >50%
positive tumor cells were found. For p53 and p16, bothnuclear and cytoplasmic staining was considered as posi-
tive, although no single cases existed which just were cy-
toplasmic positive without being nuclei positive (see
Figure 1). The cut-off values were chosen from the litera-
ture (Table 2) [30-32].
IHC stainings for the proteins pRb and p21 were also
performed using the same method as described above,
and has previously been reported by our group [21].
Genotyping by pyrosequencing for the MDM2 gene
Two 10-μm-thick sections obtained from the original par-
affin blocks were transferred to an Eppendorf tube, and
DNA was purified according to the protocol provided in
the Maxwell TM 16 FFPE DNA Purification Kit (Promega,
Madison, WI, USA). To detect SNP309 (rs2279244), the
MDM2 gene was amplified by a PCR carried out in a reac-
tion volume of 30 μl containing (final concentrations)
20 mM (NH4)2SO4, 75 mM Tris–HCl (pH 9.0), 0.01%
Tween 20, each dNTP at 200 μM, 2.0 mM MgCl2, each
primer (available on request) at 1.0 μM (Invitrogen, Paisley,
UK), 0.5 U Taq DNA polymerase (Thermowhite, Saveen
Werner AB, Limhamn, Sweden), and 50 ng of DNA. The
amplification was performed at an annealing temperature
of 60°C for 35 cycles, and the reverse primer was biotiny-
lated. Single-stranded DNA was isolated from the PCR
reaction using a Pyrosequencing Vacuum Prep Worksta-
tion (Biotage AB, Uppsala, Swden) and then transferred to
a 96-well plate. The sequencing primer was annealed to
the single-stranded DNA by heating the sample to 80°C
for 2 min and subsequently allowing it to cool to
room temperature. Thereafter, the plate was placed in the
Pyrosequencing PSQ96MA system (Biotage AB, Uppsala,
Sweden) for real-time sequencing and SNP detection.
Blood samples randomly collected from a population
of 725 healthy individuals (registered in our database)
living in the same region as the study population were
tested for MDM2 polymorphism and served as refer-
ences for the frequency of such polymorphism.
Single-strand conformation analysis and Sanger
sequencing for p53
Tumor DNA was analyzed for mutations in exons 5–8
in the p53 gene. PCR primers (available on request) cov-
ering the same exons and including exon/intron borders
of the p53 gene were used to generate PCR products
from tumor DNA. After confirming the success of the
PCR, a 1-μl aliquot of the PCR product was labeled with
32P-dATP in 5–10 cycles of secondary PCR using the
same primers as in the primary PCR and then subjected
to single-strand conformation analysis (SSCA) [33,34].
SSCA
Labeled PCR products were diluted 20-fold with 50%
formamide/10 mM EDTA/0.1% SDS (containing xylene
Table 2 Antibodies for immunohistochemistry
Antibody Clone Source Dilution Abnormal Positive
p53 DO-7 DAKO 1:100 > 10% Nuclei and cytoplasm
p21 SX118 DAKO 1:50 < 10% Nuclei
p16 6H12 Novocastra 1:20 0% or > 50% Nuclei and cytoplasm
pRb G3-245 BD Pharmingen 1:100 0% or > 50% Nuclei
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denaturation at 95°C for 5 min, the samples were im-
mediately put on ice and loaded on a native 6% poly-
acrylamide gel containing 10% glycerol. Electrophoretic
separation of single-stranded DNA was performed at
10–12 W for 16–20 h. Thereafter, the gels were attached
to filter paper and dried, and then exposed to x-ray film
for 16–24 h. Shifted bands (indicating a different sec-
ondary structure) were excised, and DNA was eluted
and used in a re-amplification PCR reaction for direct
DNA sequencing.
DNA sequencing
A 3–5-μl aliquot of PCR product (collected directly
or from re-amplification of excised SSCA bands) was
used in a standard protocol for fluorescently labeled
dideoxynucleotides (BigDye, Applied Biosystems, Life
Technologies), with injection into a capillary electro-
phoresis instrument (ABI 3500, Life Technologies) for
separation and detection. The sequences that were
obtained were compared with the reference sequence
NC 000017 (www.ncbi.nlm.nih.gov), and deviations were
recorded as mutations or polymorphisms. The identified
mutations were confirmed by re-analysis (according to
the entire procedure) from a second PCR amplification
of the tumor DNA.
Statistical analysis
Descriptive statistics were used for frequencies of muta-
tions in p53 and MDM2 polymorphism. Associations be-
tween such mutations and polymorphism on the one
hand and clinicopathological and immunohistochemical
variables on the other were calculated by the chi-square
test. Cox proportional hazards analysis was performed inFigure 1 Positive (abnormal) immunohistochemical staining for p53 (a univariate and a multivariate fashion to investigate
variables in relation to recurrence and progression in
UCB, and to test for potential confounding variables and
interactions. The results of the Cox regression are pre-
sented with hazard ratios and 95% confidence intervals.
Kaplan-Meier curves were used to analyze the relative
influence of IHC-determined p16 status and p53 muta-
tions on progression and differences were calculated
with the Log rank test. All statistical analyses were per-
formed using IBM/SPSS version 19.0. P-values of ≤ 0.05
were considered to be statistically significant, and all
tests were two sided.
Results
Study-population
The 141 patients in the study population had a median
age of 73 years (range 42–93 years) and 25 (18%) were
women. Of the 141, 115 (82%) had recurrence, and 53
(38%) had progression. The intention was to follow all
patients for at least 10 years. The median observation
time was 65 months (4–192). The characteristics of the
study-population are given in Table 3.
MDM2 polymorphism, p53 mutations and IHC analysis
In all, 53 (38%) of the 141 tumors we investigated had a
mutation in the p53 gene, but there was no apparent
prevalence in any particular exon, as outlined in Table 4.
The frequencies of the MDM2 SNP309 genotypes
among the 141 patients were as follows: 59 T/T (42%),
64 T/G (45%), and 18 G/G (13%). The corresponding
rates in our database of 725 healthy individuals tested
for MDM2 polymorphism are 41%, 45%, and 14%, re-
spectively. Thus the proportion of G/G individuals is
nearly the same in our bladder cancer cohort and theleft) and p16 (right) in urinary bladder carcinoma cells.
Table 3 Characteristics of the 141 patients included in
the study
P53 mutation MDM2 TT
No Yes No Yes
88 (62%) 53 (38%) 82 (58%) 59 (42%)
Age (years)
≤73 49 (64%) 27 (36%) 44 (58%) 32 (42%)
>73 39 (60%) 26 (40%) 38 (58%) 27 (42%)
Gender
Male 72 (62%) 44 (38%) 66 (57%) 50 (43%)
Female 16 (64%) 9 (36%) 16 (64%) 9 (36%)
MDM2
TT 38 (64%) 21 (36%) - -
GG 11 (61%) 7 (39%) - -
TG 39 (61%) 25 (39%) - -
p53 mutation
Yes - - 32 (60%) 21 (40%)
No - - 50 (57%) 38 (43%)
Recurrence
Yes 75 (65%) 40 (35%) 66 (57%) 49 (43%)
No 13 (50%) 13 (50%) 16 (62%) 10 (38%)
Progression
Yes 30 (57%) 23 (43%) 27 (51%) 26 (49%)
No 58 (66%) 30 (34%) 55 (62%) 33 (38%)
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Hardy-Weinberg equilibrium, and there is no unfavor-
able factor in MDM2 polymorphism that promotes de-
velopment of UCB stage T1.
We observed a significant association between p53
mutations and p53 IHC at a staining cut-off of 50%
(Chi square 8.67, p = 0.003), whereas no such relation-
ship was seen at cut-off values lower than 50% (10%,
25%, or < 50%). There was also an association between
abnormal p16 expression and p53 mutations (Chi square
4.74, p = 0.029), and between WHO tumor grade 2 (but
not to grade 3) and p53 mutations (Chi square 6.12,
p = 0.013) (data not shown). However, it should be noted
that there were only 21 grade 2 tumors in the material.
No association was found when we analyzed MDM2
polymorphism and p53 mutations in relation to prognosis.
Table 5 summarizes the results concerning progression inTable 4 Distribution of the p53 mutations
Exon Number of patients
5 13 (9.2 %)
6 9 (6.4 %)
7 13 (9.2 %)
8 18 (12.8%)
Total 53(37.6%)relation to IHC,MDM2 polymorphism and p53mutations
(data for recurrence not shown).
In patients with a p53 mutation, Kaplan-Meier curves
showed a higher progression rate and a shorter time to
progression for those with abnormal p16 expression as
compared to those with normal p16 expression (Log rank
chi square 4.32, p = 0.038; Figure 2). For patients who
lacked a p53 mutation, no significant difference was found
between those with normal and abnormal p16 expression
(Log rank chi square 3.78, p = 0.052; Figure 3). However,
in the whole group of UCB patients, there was an associ-
ation between IHC-abnormal p16 alone and UCB pro-
gression, as previously reported by our group [21].
No association was found for pRb or p21 IHC on one
side, and MDM2 polymorphism or p53 mutations on
the other.
Discussion
SNP309 is a common polymorphism in the regulatory
region in intron 1 of MDM2, and it might influence the
cellular levels of the p53 protein and thereby promote
tumor development and progression [17]. This has been
observed in several studies concerning poor outcome of
various malignancies, such as lung cancer, breast cancer,
gastric carcinoma, and renal cell carcinoma [35-38]. The
role of a single nucleotide polymorphism in MDM2 (i.e.,
SNP309) has also been evaluated in UCB, but the results
have varied [10,39].
Here, we studied a large well-characterized group of
patients with primary stage T1 UCB, none of whom had
received intravesical BCG or chemotherapy before recur-
rence, a treatment strategy that is mandatory today.
Accordingly, these patients exhibited a natural course of
stage T1 UCB and were therefore ideal to investigate in
the present context. We found that neither MDM2 poly-
morphism nor p53 gene mutations were associated with
tumor progression in this study population. However,
there was an association between strong IHC-determined
p53 expression and p53 gene mutations. It is debatable
whether p53 mutations can be compared with p53 expres-
sion measured by IHC. Yemelyanova et al. [40] observed
concordance between p53 gene mutations and IHC-
detected p53 expression in ovarian carcinoma patients,
and those investigators obtained statistically significant
results at a cut-off value of 60% positive tumor cells. That
value is higher than the cut-off that is usually reported as
abnormal for p53 expression, which is most often 10%
positive tumor cells [41]. In our investigation, a cut-off
value of 50% was found to be associated with mutations,
and it may reflect the mutational status of p53 more
accurately than the conventional cut-off value used for the
p53 protein.
For analysis of p53 mutations, Sanger sequencing with
fluorescent dideoxynucleotides is usually not sufficiently
Table 5 Cox proportional hazards univariate and multivariate analysis of progression after primary transurethral
resection for T1 bladder carcinoma in the Southeast care region in Sweden 1992–2001
Univariate Hazard ratio (95% CI) Multivariate Hazard ratio (95% CI) p-value
LVI*
No 1.0 1.0
Suspected 1.01 (0.51–2.00) 0.84 (0.42–1.68) 0.70
Yes 3.10 (1.48–6.49) 3.84 (1.75–8.42) 0.001
p16
Abnormal 1.0 1.0
Normal 0.40 (0.23–0.74) 0.37 (0.19–0.69) 0.002
p21
Abnormal 1.0 1.0
Normal 1.93 (0.77–4.86) 1.39 (0.54–3.59) 0.50
p53
Abnormal 1.0 1.0
Normal 0.75 (0.42–1.35) 1.54 (0.84–2.82) 0.17
p53 mutation
No 1.0 1.0
Yes 1.51 (0.87–2.59) 1.28 (0.73–2.23) 0.38
MDM2 T/T
No 1.0 1.0
Yes 1.52 (0.89–2.62) 1.75 (1.00–3.06) 0.052
pRb
Abnormal 1.0 1.0
Normal 1.36 (0.70–2.65) 1.58 (0.79–3.17) 0.20
*LVI = lymphovascular invasion.
Figure 2 Kaplan-Meier curves for patients with a p53 mutation
showing that the time (months) to progression was
significantly shorter for those with abnormal (blue curve) as
compared to normal (green curve) p16 expression. (Log rank chi
square 4.32, p = 0.038).
Figure 3 Kaplan-Meier curves for patients without a p53
mutation showing that time (months) to progression was
shorter for those with abnormal (blue curve) p16 expression as
compared to those with normal (green curve) p16 expression,
although this difference was not statistically significant.
(Log rank chi square 3.78, p = 0.052).
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and therefore we also performed SSCA. The results
showed nearly 100% agreement between SSCA mobility
shifts and Sanger sequencing of excised and re-amplified
SSCA bands.
We found an association between abnormal p16 ex-
pression and mutations in p53, which may be evidence
of linkage between the p53, p16, and pRb proteins. Fur-
thermore, this observation is supported by the results of
Kaplan-Meier analysis indicating that the rate of
progression and time to progression were significantly
shorter in patients with IHC-abnormal p16 and p53
mutations. Moreover, we observed that abnormal ex-
pression of p16 alone seems to be associated, with a
worse prognosis, which has also been reported previ-
ously by us and by other authors [21,32,42,43].
MDM2 polymorphism in the current UCB patients
was tested in DNA from tumor tissue, and hence there
was a risk of bias due to chromosomal deletions on
chromosome 12 (where MDM2 is located). However,
chromosomal 12 deletions are not common in this dis-
ease, and all of the tissue specimens analyzed in our
study contained normal cells, which ensured correct
genotyping. Furthermore, the frequency of MDM2 poly-
morphism in the UCB patients, did not differ from that
noted in our reference population, and it was in Hardy-
Weinberg equilibrium, which suggests that such poly-
morphism is stable during tumor development, and
consequently there is no difference between benign and
malignant cells.
Alhopuro et al. [44] studied patients with leiomyosar-
coma, colorectal cancer, and squamous cell carcinoma of
the head and neck, and their results indicated essentially
the same proportion of individuals with MDM2 poly-
morphism as noted in our investigation. Alhopuru and
coworkers also reported that a healthy reference popula-
tion and tumor material from their study population had
approximately the same frequencies of MDM2 poly-
morphism. Onat et al. [45] analyzed MDM2 polymorph-
ism in bladder cancer and found an association between
development of the disease and MDM2 polymorphism
in patients with the G/G genotype. The frequency of
MDM2 G/G in their study was somewhat greater in the
tumor population than in the control group consisting
of healthy individuals, although the values those resear-
chers obtained differ very little from the levels noted in
our investigation. In an assessment of B-CLL patients,
Willander et al. [46] found that overall survival was poorer
in the subjects with one or two G alleles compared to
those with T/T. However, the overall frequencies of G/G,
T/G, and T/T found by those investigators are equivalent
to the corresponding figures recorded in our study, which
underlines that the MDM2 gene is probably rather stable
throughout tumor development and that one or two Galleles more likely only play a role as an unfavorable
genotype.
Several studies have examined p53 and MDM2 poly-
morphism in UCB. In one of those investigations, Lu
et al. [47] found that 61 (44%) of 140 patients with the
disease were wild type for p53, whereas the correspond-
ing proportion in our cohort was 62%, and this disparity
may reflect difference in T stages between the two stud-
ies. A plausible explanation for this is that the tumors
investigated by Lu and colleagues were from cystectomy
specimens and thus represented higher tumor stages
with more p53 mutations (less wild-type p53). Notably,
we focused on exons 5–8 in the p53 gene, whereas Lu
et al. investigated exons 2–11, although only a small
number of the mutations in their study were found
outside exons 5–8. Furthermore, Hernandez et al. [48]
found a frequency of 65.5% p53 mutations in a group of
patients with stage T1 grade 3 UCB, but those mutations
were not associated with prognosis; interestingly, exons
4–9 were evaluated in that investigation, but the majo-
rity of the mutations were found in exons 5–8.
The frequency of p53 gene mutations varies conside-
rably in the literature, which may reflect the general
heterogeneity of stage T1 UCB as a type of malignancy.
It is possible that mutations in this gene play a role in
the development and progression of T1 UCB, but the
definitive pathways have not yet been completely elu-
cidated.
Conclusions
Polymorphism in MDM2 (SNP309) and mutations in
p53 were not associated with worse prognosis in this
population-based cohort of patients with stage T1 UCB.
Mutations in p53 were associated with an IHC cut-off
value of 50% for the p53 protein. Patients with IHC-
abnormal p16 and p53 mutations had a higher rate of
progression and a shorter time to progression.
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